Expanding the genetic spectrum of TUBB1-related thrombocytopenia.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 12 2021
Historique:
received: 16 12 2020
accepted: 20 06 2021
pubmed: 14 9 2021
medline: 8 1 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

β1-Tubulin plays a major role in proplatelet formation and platelet shape maintenance, and pathogenic variants in TUBB1 lead to thrombocytopenia and platelet anisocytosis (TUBB1-RT). To date, the reported number of pedigrees with TUBB1-RT and of rare TUBB1 variants with experimental demonstration of pathogenicity is limited. Here, we report 9 unrelated families presenting with thrombocytopenia carrying 6 β1-tubulin variants, p.Cys12LeufsTer12, p.Thr107Pro, p.Gln423*, p.Arg359Trp, p.Gly109Glu, and p.Gly269Asp, the last of which novel. Segregation studies showed incomplete penetrance of these variants for platelet traits. Indeed, most carriers showed macrothrombocytopenia, some only increased platelet size, and a minority had no abnormalities. Moreover, only homozygous carriers of the p.Gly109Glu variant displayed macrothrombocytopenia, highlighting the importance of allele burden in the phenotypic expression of TUBB1-RT. The p.Arg359Trp, p.Gly269Asp, and p.Gly109Glu variants deranged β1-tubulin incorporation into the microtubular marginal ring in platelets but had a negligible effect on platelet activation, secretion, or spreading, suggesting that β1-tubulin is dispensable for these processes. Transfection of TUBB1 missense variants in CHO cells altered β1-tubulin incorporation into the microtubular network. In addition, TUBB1 variants markedly impaired proplatelet formation from peripheral blood CD34+ cell-derived megakaryocytes. Our study, using in vitro modeling, molecular characterization, and clinical investigations provides a deeper insight into the pathogenicity of rare TUBB1 variants. These novel data expand the genetic spectrum of TUBB1-RT and highlight a remarkable heterogeneity in its clinical presentation, indicating that allelic burden or combination with other genetic or environmental factors modulate the phenotypic impact of rare TUBB1 variants.

Identifiants

pubmed: 34516618
pii: 476873
doi: 10.1182/bloodadvances.2020004057
pmc: PMC8714720
doi:

Substances chimiques

TUBB1 protein, human 0
Tubulin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5453-5467

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Platelets. 2021 Nov 17;32(8):1108-1112
pubmed: 33400601
Blood. 2009 Jan 8;113(2):458-61
pubmed: 18849486
Haematologica. 2019 Jul;104(7):1473-1481
pubmed: 30655369
Thromb Res. 2000 Aug 15;99(4):353-61
pubmed: 10963786
Haematologica. 2018 Jan;103(1):148-162
pubmed: 28983057
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Platelets. 2017 Jan;28(1):3-13
pubmed: 27161842
Haematologica. 2020 Aug;105(8):2004-2019
pubmed: 32527953
Haematologica. 2016 Oct;101(10):1170-1179
pubmed: 27479822
Thromb Haemost. 2017 Nov;117(11):2079-2091
pubmed: 29044293
Blood Coagul Fibrinolysis. 2013 Dec;24(8):798-808
pubmed: 24030121
Cell Motil Cytoskeleton. 1995;31(4):259-72
pubmed: 7553913
Int J Mol Sci. 2019 Jul 16;20(14):
pubmed: 31315202
Clin Genet. 2017 Jun;91(6):924-926
pubmed: 27905099
Front Cardiovasc Med. 2019 Jun 19;6:80
pubmed: 31275945
Hum Mutat. 2020 Jan;41(1):277-290
pubmed: 31562665
Curr Biol. 2017 Dec 4;27(23):R1287-R1292
pubmed: 29207274
Thromb Haemost. 2018 Jun;118(6):1009-1020
pubmed: 29695020
Haematologica. 2018 Jun;103(6):e259-e263
pubmed: 29439184
Br J Haematol. 2013 Jan;160(2):237-43
pubmed: 23157319
Blood. 2019 Dec 5;134(23):2082-2091
pubmed: 31064749
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30446499
Br J Haematol. 2019 Jun;185(5):888-902
pubmed: 30854628
Blood Adv. 2018 Sep 25;2(18):2341-2346
pubmed: 30232087
Haematologica. 2017 Jul;102(7):1192-1203
pubmed: 28385783
Blood. 2008 May 1;111(9):4605-16
pubmed: 18230754
Eur J Haematol. 2014 Apr;92(4):276-82
pubmed: 24344610
Haematologica. 2020 Mar;105(3):e124-e128
pubmed: 31221775
J Thromb Haemost. 2010 Sep;8(9):2063-5
pubmed: 20626619
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):385-399
pubmed: 29222283
Biomol Ther (Seoul). 2017 May 1;25(3):223-230
pubmed: 27871158
Curr Opin Hematol. 2016 Sep;23(5):486-92
pubmed: 27438527
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33926054
Haematologica. 2007 Apr;92(4):513-8
pubmed: 17488662
Semin Thromb Hemost. 2019 Oct;45(7):695-707
pubmed: 31041795
PLoS One. 2012;7(4):e34449
pubmed: 22539947
J Thromb Haemost. 2020 Mar;18(3):732-739
pubmed: 31750621
J Thromb Haemost. 2015 Apr;13(4):651-9
pubmed: 25529050
Cancer Res. 2012 Sep 15;72(18):4744-52
pubmed: 22805305
Trends Biochem Sci. 1988 Sep;13(9):339-43
pubmed: 3072712
Platelets. 2018 Mar;29(2):209-211
pubmed: 29333906
J Clin Med. 2021 Feb 02;10(3):
pubmed: 33540538
Blood. 2005 Oct 1;106(7):2356-62
pubmed: 15956286
Blood. 2016 Sep 1;128(9):1282-9
pubmed: 27235135
Blood Adv. 2019 Oct 22;3(20):2962-2979
pubmed: 31648317
Orphanet J Rare Dis. 2014 Dec 24;9:213
pubmed: 25539746
Haematologica. 2020 Apr;105(4):870-887
pubmed: 32165484
J Thromb Haemost. 2019 Sep;17(9):1430-1439
pubmed: 31220402
Nat Genet. 2014 Jun;46(6):629-34
pubmed: 24777453
Blood Adv. 2021 Jan 26;5(2):414-431
pubmed: 33496739
Haematologica. 2021 May 01;106(5):1368-1380
pubmed: 32327502
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Br J Haematol. 2013 Jul;162(1):112-9
pubmed: 23617394
Curr Biol. 2001 Apr 17;11(8):579-86
pubmed: 11369202
Thromb Haemost. 2011 May;105(5):855-63
pubmed: 21384078
Nat Commun. 2012 May 22;3:852
pubmed: 22617292

Auteurs

Verónica Palma-Barqueros (V)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Loredana Bury (L)

Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Shinji Kunishima (S)

Department of Medical Technology, Gifu University of Medical Science, Seki, Japan.

María Luisa Lozano (ML)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Augustín Rodríguez-Alen (A)

Servicio de Hematología y Hemoterapia, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, Spain.

Nuria Revilla (N)

Servicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.

Natalia Bohdan (N)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

José Padilla (J)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

María P Fernández-Pérez (MP)

Servicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.

María Eugenia de la Morena-Barrio (ME)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Ana Marín-Quilez (A)

Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas.

Rocío Benito (R)

Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas.

María F López-Fernández (MF)

Servicio Hematología y Hemoterapia, Complejo Hospitalario Universitario A Coruña, Spain.

Shally Marcellini (S)

Servicio Hematología, Hospital General, Segovia, Spain; and.

Ana Zamora-Cánovas (A)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Vicente Vicente (V)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Constantino Martínez (C)

Servicio de Hematología, Hospital Universitario Hospital Universitario Ramón y Cajal, Madrid, Spain.

Paolo Gresele (P)

Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

José M Bastida (JM)

Departamento de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.

José Rivera (J)

Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano de Investigación Biosanitaria-Arrixaca, Centro de Investigacién Biomódica en Red de Enfermedades Raras-U765, Murcia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH